(Q43278551)

18 November 2017

title

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily (English)

1 reference

18 November 2017

1 reference

dasatinib monohydrate

1 reference

1 reference

8

1 reference

18 November 2017

9

1 reference

18 November 2017

H Herrmann

2

0 references

author name string

C Sillaber

1

1 reference

18 November 2017

K Bennett

3

1 reference

18 November 2017

U Rix

4

1 reference

18 November 2017

C Baumgartner

5

1 reference

18 November 2017

A Böhm

6

1 reference

18 November 2017

S Herndlhofer

7

1 reference

18 November 2017

U Jäger

10

1 reference

18 November 2017

P Valent

11

1 reference

18 November 2017

language of work or name

1 reference

9 September 2009

1 reference

European Journal of Clinical Investigation

18 November 2017

published in

1 reference

18 November 2017

volume

39

1 reference

18 November 2017

issue

12

1 reference

18 November 2017

page(s)

1098-1109

1 reference

Optimizing therapy of chronic myeloid leukemia

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Current and emerging treatment options in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Profound inhibition of antigen-specific T-cell effector functions by dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Establishment of an immature mast cell line from a patient with mast cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2009.02206.X

10.1111/J.1365-2362.2009.02206.X

21 January 2018

Identifiers

DOI

1 reference

18 November 2017

1 reference